This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Description, Dosage, Side Effects, Contraindications. Data from EMA, URPL, openFDA and other regulatory sources.
| Paracetamol | Ibuprofen | |
|---|---|---|
| Active Substances | Paracetamol | IBUPROFEN |
| ATC Code | N02BE01 | C01EB16 |
| Form | Tabletki musujące | TABLET, COATED |
| Dosage | 1 g | 200 mg/1 |
| Route | doustna | ORAL |
| Manufacturer | Medezin Sp. z o.o. | Haleon US Holdings LLC |
| Indications | For rapid relief of pain including migraine, headache, period pains, neuralgia, toothache, sore throat. Symptomatic relief of rheumatic pain, sciatica, lumbago, fibrositis, muscular aches and pains. Symptomatic relief of influenza, feverishness, feverish colds. | — |
| Side Effects | Acetylsalicylic acid: The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS III categories of frequency is not possible. Blood and lymphatic system disorders Increased risk of bleeding (due to effect on platelet aggregation). In the context of bleeding: haemorrhagic anaemia, iron deficiency anaemia with the respective laboratory and clinical signs and symptoms. In the context of glucose-6-phosphate dehydrogenase (G6PD) deficiency: haemolysis, haemolytic anaemia Immune system disorders Hypersensitivity, drug hypersensitivity, allergic edema and angioedema, anaphylactic reaction, anaphylactic shock with respective laboratory and clinical manifestations Nervous system disorders Cerebral and intracranial haemorrhage, dizziness Ear and labyrinth disorders Tinnitus Cardiac disorders In the context of severe allergic reactions: cardio-respiratory distress Vascular disorders Haemorrhage, operative haemorrhage, haematoma, muscle haemorrhage Respiratory, thoracic and mediastinal disorders Epistaxis, analgesic asthma syndrome, rhinitis, nasal congestion, bronchospasm Gastrointestinal disorders Dyspepsia, gastrointestinal pain, abdominal pain, gingival bleeding, gastrointestinal inflammation, gastrointestinal ulcer, gastrointestinal haemorrhage, gastrointestinal ulcer perforation with the respective laboratory and clinical signs and symptoms, nausea, diarrhoea, vomiting Hepatobiliary disorders Liver disorder, transaminases increased Skin and subcutaneous tissue disorders Rash, urticaria, pruritus, severe skin reactions Renal and urinary disorders Impaired renal function Injury, poisoning and procedural complications See overdose section Paracetamol: Adverse effects of paracetamol are rare but hypersensitivity including skin rash may occur. Very rare cases of serious skin reactions have been reported. There have been reports of blood dyscrasis including thrombocytopenia and agranulocytosis, but these were not necessarily causally related to paracetamol. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. |
Paracetamol (INN: Paracetamol, ATC N02BE01) and Ibuprofen (INN: IBUPROFEN, ATC C01EB16) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
| — |
| Contraindications | Alka-Seltzer XS should not be administered to patients: • with known hypersensitivity (e.g. bronchospasm, rhinitis, urticaria) to acetylsalicylic acid or other salicylates, paracetamol, caffeine or to any other components of the product • with a history of hypersensitivity reactions (e.g. asthma, rhinitis, urticaria) induced by the administration of salicylates, or substances with similar actions, notably non-steroidal anti-inflammatory drugs. • with active or a history of peptic ulcers. • with haemorrhagic diathesis such as haemophilia. • with severe renal failure. • with severe hepatic failure. • with severe cardiac failure. • in the third trimester of pregnancy (see section 4.6). • who are breastfeeding. • receiving doses of methotrexate at 15mg/week or greater (see section 4.5). | — |
|---|
| Warnings | None applicable. | — |
|---|